Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020111325 - PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT

Publication Number WO/2020/111325
Publication Date 04.06.2020
International Application No. PCT/KR2018/014944
International Filing Date 29.11.2018
IPC
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A23L 33/10 2016.01
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
CPC
A23L 33/10
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • 국립암센터 NATIONAL CANCER CENTER [KR]/[KR]
  • 한국화학연구원 KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY [KR]/[KR]
Inventors
  • 김경태 KIM, Kyungtae
  • 이병일 LEE, Byung Il
  • 박중원 PARK, Joong-Won
  • 이은숙 LEE, Eun Sook
  • 이상진 LEE, Sang Jin
  • 봉승민 BONG, Seoung Min
  • 김진숙 KIM, Jin Sook
  • 박민지 PARK, Minji
  • 윤은경 YOON, Eun-Kyung
  • 이주연 LEE, Joo-Youn
  • 이수형 LEE, Su-Hyung
Agents
  • 이명진 LEE, Myoung-Jin
Priority Data
10-2018-014911228.11.2018KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT
(FR) COMPOSITION PHARMACEUTIQUE PERMETTANT DE PRÉVENIR OU DE TRAITER LE CANCER CONTENANT UN INHIBITEUR DE L'ACTIVATION DE PLK1 EN TANT QUE PRINCIPE ACTIF
(KO) PLK1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
Abstract
(EN)
The present invention relates to a pharmaceutical composition for preventing, treating or alleviating cancer, containing an activation Inhibitor of PLK1 as an active ingredient, and a compound according to the present invention selectively binds to PBD of PLK1, thereby having advantages of high selectivity and binding affinity for PLK1 and low toxicity. Therefore, a PLK1 activation inhibitor compound according to the present invention can be effectively used as an anticancer agent by inhibiting the growth of various cancer cells, and can be expected to exhibit synergistic effects with existing developed anticancer agents through co-administration, in addition to individual administration thereof.
(FR)
La présente invention concerne une composition pharmaceutique destinée à prévenir, traiter ou soulager le cancer, contenant un inhibiteur de l'activation de PLK1 en tant que principe actif, et un composé selon la présente invention se lie sélectivement à PBD de PLK1, ce qui présente les avantages d'une sélectivité et d'une affinité de liaison à PLK1 élevées et d'une faible toxicité. Par conséquent, le composé inhibiteur de l'activation de PLK1 selon la présente invention peut être utilisé efficacement en tant qu'agent anticancéreux par inhibition de la croissance de diverses cellules cancéreuses et peut, en prévision, présenter des effets synergiques avec des agents anticancéreux existants par co-administration en plus de son administration individuelle.
(KO)
본 발명은 PLK1의 활성 억제제를 유효성분으로 포함하는 암 예방, 치료 또는 개선용 약학적 조성물에 관한 것으로 본 발명에 따른 상기 화합물은 PLK1의 PBD에 선택적으로 결합함으로써, PLK1에 대한 높은 선택성과 결합친화성, 및 저독성의 이점을 갖는다. 따라서, 본 발명에 따른 PLK1 활성 억제제 화합물은 다양한 암세포의 성장을 저해함으로써 항암제로 유용하게 이용될 수 있을 것이며, 단독투여 이외에도 기존에 개발된 항암제와의 병용투여를 통한 시너지효과를 기대할 수 있다.
Also published as
Latest bibliographic data on file with the International Bureau